Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20991798 | 0.80 | GABRA1 (0.47) | GABRA1GABRB1 | |
| SCHEMBL25834787 | 0.80 | GABRA1 (0.47) | GABRA1GABRB1POLBGAAGFER | |
| SCHEMBL20681258 | 0.80 | GABRA1 (0.64) | GABRA1GABRB1CA1CA2LMNA | |
| SCHEMBL6765852 | 0.79 | GABRA1 (0.45) | GABRA1GABRB1LMNA | |
| SCHEMBL22899728 | 0.78 | GABRA1 (0.61) | GABRA1GABRB1CA1CA2LMNA | |
| SCHEMBL20636510 | 0.77 | LMNA (0.42) | GABRA1GABRB1CA1CA2LMNA | |
| SCHEMBL3640323 | 0.76 | GABRA1 (1.00) | GABRA1GABRB1CA1CA2LMNA | |
| SCHEMBL22774086 | 0.76 | GABRA1 (0.58) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL839941 | 0.76 | GABRA1 (0.58) | GABRA1GABRB1CA1CA2LMNA | |
| SCHEMBL636376 | 0.76 | GABRA1 (0.58) | GABRA1GABRB1CA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009566-A1 | N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-3137574-B1 | ORGANIC MOLECULES FOR USE AS EMITTERS | CYNORA GMBH (DE) | 2018-04-04 | — | — | EP | disclosed |
| US-20170288149-A1 | ORGANIC MOLECULES FOR USE AS EMITTERS | CYNORA GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-9281483-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-9281483-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150287935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150287935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8889864-B2 | Metal complexes of cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889864-B2 | Metal complexes of cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150287935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LIG1, L1CAM, LIG3 | GABRA1 498/4885GABRB1 1283/4885CA1 4086/4885 |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | GABRA1 432/4885GABRB1 1628/4885CA1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.